(19)
(11) EP 4 384 152 A1

(12)

(43) Date of publication:
19.06.2024 Bulletin 2024/25

(21) Application number: 22856484.5

(22) Date of filing: 09.08.2022
(51) International Patent Classification (IPC): 
A61K 31/00(2006.01)
A61P 35/00(2006.01)
A61K 31/136(2006.01)
A61K 31/473(2006.01)
A61K 39/395(2006.01)
C07K 16/28(2006.01)
A61K 31/337(2006.01)
(52) Cooperative Patent Classification (CPC):
Y02A 50/30; A61K 31/337; A61P 35/00; C07K 16/2818; A61K 2039/507; C07K 2317/565; C07K 16/2803; C07K 2317/56; A61K 2039/545; A61K 2039/55; A61K 39/39558; A61K 45/06; A61K 31/513; A61K 33/243; A61K 31/7068; A61K 31/555
 
C-Sets:
  1. A61K 31/7068, A61K 2300/00;
  2. A61K 31/555, A61K 2300/00;
  3. A61K 39/39558, A61K 2300/00;
  4. A61K 31/513, A61K 2300/00;
  5. A61K 33/243, A61K 2300/00;
  6. A61K 31/337, A61K 2300/00;

(86) International application number:
PCT/US2022/039767
(87) International publication number:
WO 2023/018677 (16.02.2023 Gazette 2023/07)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 10.08.2021 US 202163231525 P
04.04.2022 US 202263327070 P

(71) Applicant: Merck Sharp & Dohme LLC
Rahway, New Jersey 07065 (US)

(72) Inventors:
  • HEALY, Jane Anne
    Rahway, New Jersey 07065-0907 (US)
  • SHRAWANKUMAR JHA, Sujata
    Dallas, Texas 75230 (US)
  • KEENAN, Tanya
    Boston, Massachusetts 02115-5727 (US)
  • SIEGEL, Abby
    Rahway, New Jersey 07065-0907 (US)
  • PINHEIRO, Elaine, M.
    Needham, Massachusetts 02494 (US)
  • SNYDER, Alexandra
    New York, New York 10028 (US)
  • CAI, Mingmei
    Boston, Massachusetts 02115-5727 (US)

(74) Representative: Merck Sharp & Dohme LLC 
120 Moorgate
London EC2M 6UR
London EC2M 6UR (GB)

   


(54) A THERAPEUTIC COMBINATION COMPRISING A T1GIT ANTAGONIST, A PD-1 ANTAGONIST, AND A CHEMOTHERAPEUTIC AGENT(S)